ReviewNature reviews. Nephrology2009
Chemotherapy-associated renal dysfunction.
Review in Nature reviews. Nephrology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Predicting adverse drug event using machine learning based on electronic health records: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Combinatorial in situ cancer vaccines: unlocking broad and enhanced antitumor responses.Signal transduction and targeted therapy · 2026Review
- Association between albumin-corrected anion gap and in-hospital mortality in ICU patients with lung cancer: a retrospective cohort study based on the MIMIC database.Journal of thoracic disease · 2026Article
- The IQGAP1-claudin cell junction axis in cisplatin-induced epithelial damage.Cell communication and signaling : CCS · 2026Article
- Cisplatin-incorporating gelatin-coated gadolinium oxide nanoparticles for cancer theranostics.iScience · 2026Article
- Trend and Cancer-Specific Prevalence of Kidney Stones Among US Cancer Survivors, 2007-2020.Current oncology (Toronto, Ont.) · 2025Article
- Adjuvant Chemotherapy for Patients With Chronic Kidney Disease: A Study on Treatment Adoption and Associated Factors.Cancer medicine · 2025Article
- Article
- Sepsis with Cancer is Marked by a Dysregulated Myeloid Cell Compartment: A Pilot Study.Journal of inflammation research · 2025Article
- Nanotechnology-Based Drug Delivery Systems for Treating Acute Kidney Injury.ACS biomaterials science & engineering · 2024Review
- Ultrasmall Nanodots with Dual Anti-Ferropototic Effect for Acute Kidney Injury Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- STING activation disrupts tumor vasculature to overcome the EPR limitation and increase drug deposition.Science advances · 2024Article
- Hematological and blood biochemistry parameters as prognostic indicators of survival in canine multicentric lymphoma treated with COP and L-COP protocols.Veterinary world · 2024Article
- Kidney and Urinary Tract Involvement in Chronic Myelomonocytic Leukemia.Kidney medicine · 2024Review
- Ifosfamide-induced nephrogenic diabetes insipidus and Fanconi syndrome in a patient with femur osteosarcoma.Caspian journal of internal medicine · 2024Article
- Chasing Graphene-Based Anticancer Drugs: Where are We Now on the Biomedical Graphene Roadmap?International journal of nanomedicine · 2024Review
- Golden Buckwheat Extract-Loaded Injectable Hydrogel for Efficient Postsurgical Prevention of Local Tumor Recurrence Caused by Residual Tumor Cells.Molecules (Basel, Switzerland) · 2023Article
- Effects of Exercise Preconditioning on Doxorubicin-Induced Liver and Kidney Toxicity in Male and Female Rats.International journal of molecular sciences · 2023Article
- Ferroptosis MRI for early detection of anticancer drug-induced acute cardiac/kidney injuries.Science advances · 2023Article
- The renal damage and mechanisms relevant to antitumoral drugs.Frontiers in oncology · 2023Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The presence of renal dysfunction in a patient receiving chemotherapy can be devastating. Although many patients with cancer have underlying compromised renal function, some chemotherapeutic agents can actually induce renal abnormalities. An understanding of which traditional and newer chemotherapy agents can affect renal function is useful for physicians so that they can monitor patients for renal abnormalities and initiate preventive strategies to minimize renal complications. This Review highlights renal abnormalities associated with current chemotherapy agents and provides suggestions for preventive measures.
Indexed as
Identifiers
19564889What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.